Marianne G Rots

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5944540/publications.pdf Version: 2024-02-01



MADIANNE C. POTS

#	Article	IF	CITATIONS
1	The timeline of epigenetic drug discovery: from reality to dreams. Clinical Epigenetics, 2019, 11, 174.	4.1	275
2	EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis, 2010, 31, 1913-1921.	2.8	270
3	Writing of H3K4Me3 overcomes epigenetic silencing in a sustained but context-dependent manner. Nature Communications, 2016, 7, 12284.	12.8	195
4	Epigenetic reprogramming of cancer cells via targeted DNA methylation. Epigenetics, 2012, 7, 350-360.	2.7	189
5	Epigenetic Editing: targeted rewriting of epigenetic marks to modulate expression of selected target genes. Nucleic Acids Research, 2012, 40, 10596-10613.	14.5	150
6	Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer. Nucleic Acids Research, 2012, 40, 6725-6740.	14.5	138
7	Targeted Methylation and Gene Silencing of VEGF-A in Human Cells by Using a Designed Dnmt3a–Dnmt3L Single-Chain Fusion Protein with Increased DNA Methylation Activity. Journal of Molecular Biology, 2013, 425, 479-491.	4.2	138
8	Induced DNA demethylation by targeting Ten-Eleven Translocation 2 to the human ICAM-1 promoter. Nucleic Acids Research, 2014, 42, 1563-1574.	14.5	132
9	Epigenetic editing of the Dlg4/PSD95 gene improves cognition in aged and Alzheimer's disease mice. Brain, 2017, 140, 3252-3268.	7.6	121
10	The influence of eukaryotic chromatin state on CRISPR–Cas9 editing efficiencies. Current Opinion in Biotechnology, 2019, 55, 68-73.	6.6	96
11	Mitochondrial epigenetics: an overlooked layer of regulation?. Trends in Genetics, 2015, 31, 353-356.	6.7	85
12	Therapeutic modulation of endogenous gene function by agents with designed DNA-sequence specificities. Nucleic Acids Research, 2003, 31, 6064-6078.	14.5	84
13	Towards Sustained Silencing of HER2/neu in Cancer By Epigenetic Editing. Molecular Cancer Research, 2013, 11, 1029-1039.	3.4	72
14	Local chromatin microenvironment determines DNMT activity: from DNA methyltransferase to DNA demethylase or DNA dehydroxymethylase. Epigenetics, 2015, 10, 671-676.	2.7	72
15	Experimental mitochondria-targeted DNA methylation identifies GpC methylation, not CpG methylation, as potential regulator of mitochondrial gene expression. Scientific Reports, 2017, 7, 177.	3.3	72
16	Regulation of mitochondrial gene expression the epigenetic enigma. Frontiers in Bioscience - Landmark, 2017, 22, 1099-1113.	3.0	69
17	Missing heritability: is the gap closing? An analysis of 32 complex traits in the Lifelines Cohort Study. European Journal of Human Genetics, 2017, 25, 877-885.	2.8	67
18	Engineering Zinc Finger Protein Transcription Factors: The Therapeutic Relevance of Switching Endogenous Gene Expression On or Off at Command. Journal of Molecular Biology, 2005, 354, 507-519.	4.2	55

MARIANNE G ROTS

#	Article	IF	CITATIONS
19	Advances of epigenetic editing. Current Opinion in Chemical Biology, 2020, 57, 75-81.	6.1	54
20	Epigenetic Editing: On the Verge of Reprogramming Gene Expression at Will. Current Genetic Medicine Reports, 2016, 4, 170-179.	1.9	52
21	Procollagen Lysyl Hydroxylase 2 Expression Is Regulated by an Alternative Downstream Transforming Growth Factor β-1 Activation Mechanism. Journal of Biological Chemistry, 2015, 290, 28465-28476.	3.4	48
22	Epigenetics: The neglected key to minimize learning and memory deficits in Down syndrome. Neuroscience and Biobehavioral Reviews, 2014, 45, 72-84.	6.1	47
23	Functional validation of putative tumor suppressor gene <i>C13ORF18</i> in cervical cancer by Artificial Transcription Factors. Molecular Oncology, 2013, 7, 669-679.	4.6	39
24	Epigenetic drugs: from chemistry via biology to medicine and back. Clinical Epigenetics, 2016, 8, 56.	4.1	39
25	Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer. Breast Cancer Research, 2014, 16, 412.	5.0	38
26	Nrf2, the master redox switch: The Achilles' heel of ovarian cancer?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 494-509.	7.4	36
27	The potential for targeted rewriting of epigenetic marks in COPD as a new therapeutic approach. , 2018, 182, 1-14.		36
28	Targeted epigenetic editing of SPDEF reduces mucus production in lung epithelial cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2017, 312, L334-L347.	2.9	35
29	Re-expression of Selected Epigenetically Silenced Candidate Tumor Suppressor Genes in Cervical Cancer by TET2-directed Demethylation. Molecular Therapy, 2016, 24, 536-547.	8.2	33
30	Epigenetic Regulation of S100A9 and S100A12 Expression in Monocyte-Macrophage System in Hyperglycemic Conditions. Frontiers in Immunology, 2020, 11, 1071.	4.8	32
31	Upregulation of endogenous ICAMâ€1 reduces ovarian cancer cell growth in the absence of immune cells. International Journal of Cancer, 2014, 134, 280-290.	5.1	31
32	Prolonged re-expression of the hypermethylated gene <i>EPB41L3</i> using artificial transcription factors and epigenetic drugs. Epigenetics, 2015, 10, 384-396.	2.7	28
33	Engineering zinc finger protein transcription factors to downregulate the epithelial glycoprotein-2 promoter as a novel anti-cancer treatment. Molecular Carcinogenesis, 2007, 46, 391-401.	2.7	27
34	Targeted DNA Methylation by a DNA Methyltransferase Coupled to a Triple Helix Forming Oligonucleotide To Down-Regulate the Epithelial Cell Adhesion Molecule. Bioconjugate Chemistry, 2010, 21, 1239-1245.	3.6	25
35	Folic acid conjugates of a bleomycin mimic for selective targeting of folate receptor positive cancer cells. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1922-1927.	2.2	25
36	Virus–host interplay in hepatitis B virus infection and epigenetic treatment strategies. FEBS Journal, 2017, 284, 3550-3572.	4.7	24

MARIANNE G ROTS

#	Article	IF	CITATIONS
37	Efficient Nuclear DNA Cleavage in Human Cancer Cells by Synthetic Bleomycin Mimics. ACS Chemical Biology, 2014, 9, 1044-1051.	3.4	23
38	Importance of Metal-Ion Exchange for the Biological Activity of Coordination Complexes of the Biomimetic Ligand N4Py. Inorganic Chemistry, 2018, 57, 7748-7756.	4.0	23
39	Epiproteome profiling of cadmiumâ€transformed human bronchial epithelial cells by quantitative histone postâ€translational modification–enzymeâ€linked immunosorbent assay. Journal of Applied Toxicology, 2018, 38, 888-895.	2.8	22
40	The past and presence of gene targeting: from chemicals and DNA via proteins to RNA. Philosophical Transactions of the Royal Society B: Biological Sciences, 2018, 373, 20170077.	4.0	20
41	Persistent downregulation of the pancarcinomaâ€associated epithelial cell adhesion molecule <i>via</i> active intranuclear methylation. International Journal of Cancer, 2008, 123, 484-489.	5.1	19
42	Editing the Epigenome: Overview, Open Questions, and Directions of Future Development. Methods in Molecular Biology, 2018, 1767, 3-18.	0.9	19
43	Exploiting epigenetics for the treatment of inborn errors of metabolism. Journal of Inherited Metabolic Disease, 2020, 43, 63-70.	3.6	18
44	Targeting Nrf2 in healthy and malignant ovarian epithelial cells: Protection versus promotion. Molecular Oncology, 2015, 9, 1259-1273.	4.6	17
45	The Endothelium as a Target for Anti-Atherogenic Therapy: A Focus on the Epigenetic Enzymes EZH2 and SIRT1. Journal of Personalized Medicine, 2021, 11, 103.	2.5	16
46	A Role for MeCP2 in Switching Gene Activity via Chromatin Unfolding and HP1Î ³ Displacement. PLoS ONE, 2013, 8, e69347.	2.5	13
47	Step into the Groove: Engineered Transcription Factors as Modulators of Gene Expression. Advances in Genetics, 2006, 56, 131-161.	1.8	12
48	RASSF1C oncogene elicits amoeboid invasion, cancer stemness, and extracellular vesicle release via a SRC/Rho axis. EMBO Journal, 2021, 40, e107680.	7.8	12
49	TCTN2: a novel tumor marker with oncogenic properties. Oncotarget, 2017, 8, 95256-95269.	1.8	9
50	Rewriting DNA Methylation Signatures at Will: The Curable Genome Within Reach?. Advances in Experimental Medicine and Biology, 2016, 945, 475-490.	1.6	8
51	The Mitochondrial Epigenome: An Unexplored Avenue to Explain Unexplained Myopathies?. International Journal of Molecular Sciences, 2022, 23, 2197.	4.1	7
52	Ubiquitin carboxyl-terminal hydrolase isozyme L1/UCHL1 suppresses epithelial–mesenchymal transition and is under-expressed in cadmium-transformed human bronchial epithelial cells. Cell Biology and Toxicology, 2021, 37, 497-513.	5.3	6
53	KRAB-Induced Heterochromatin Effectively Silences PLOD2 Gene Expression in Somatic Cells and Is Resilient to TGFÎ ² 1 Activation. International Journal of Molecular Sciences, 2020, 21, 3634.	4.1	6
54	Establishment of Cell Lines Stably Expressing dCas9-Fusions to Address Kinetics of Epigenetic Editing. Methods in Molecular Biology, 2018, 1767, 395-415.	0.9	3

#	Article	IF	CITATIONS
55	Re-expressing Epigenetically Silenced Genes by Inducing DNA Demethylation Through Targeting of Ten-Eleven Translocation 2 to Any Given Genomic Locus. Methods in Molecular Biology, 2017, 1654, 321-335.	0.9	2